0001683168-23-007924.txt : 20231113 0001683168-23-007924.hdr.sgml : 20231113 20231113090015 ACCESSION NUMBER: 0001683168-23-007924 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41282 FILM NUMBER: 231395585 BUSINESS ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 BUSINESS PHONE: 514-426-6161 MAIL ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 8-K 1 sunshine_8k.htm FORM 8-K
false 0001402328 0001402328 2023-11-13 2023-11-13 0001402328 us-gaap:CommonStockMember 2023-11-13 2023-11-13 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2023-11-13 2023-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2023

 

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Colorado 001-41282 20-5566275

(State or other jurisdiction

of incorporation)

 (Commission File Number) (IRS Employer ID No.)

 

6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R0A5

(Address of principal executive offices) (zip code)

 

(514) 426-6161

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Common Stock Purchase Warrants SBFMW The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 13, 2023, Sunshine Biopharma, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the period ended September 30, 2023. The press release is attached hereto as Exhibit 99.1.

 

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(b) Exhibits. The following exhibits are included in this report:

 

No. Description
99.1 Press Release
104 Cover Page Interactive Data File (formatted in iXBRL)

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 13, 2023 SUNSHINE BIOPHARMA, INC.
   
   
  By: /s/ Dr. Steve N. Slilaty                          
  Dr. Steve N. Slilaty, Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 3 
 EX-99.1 2 sunshine_ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

November 13, 2023

 

 

SUNSHINE BIOPHARMA REPORTS 2023 THIRD QUARTER RESULTS:

REVENUES UP SIGNIFICANTLY OVER LAST YEAR DUE TO A KEY ACQUISITION

 

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 third quarter. The Company reported gross revenues of $5,957,668 for the quarter ended September 30, 2023, an increase of $5,824,860 over the same period in 2022. The increase was due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October 2022. In addition, the Company’s third quarter revenues of $5,957,668 represented a 7.1% increase over the second quarter results of $5,560,865 and a 21.7% increase over the first quarter results of $4,894,053.

 

The Company incurred a net loss from operations of $651,482 ($0.04 per share) for the three months ended September 30, 2023, compared to a net loss of $1,457,019 ($0.12 per share) during the comparable period in 2022.

 

“We are excited about our 2023 quarterly revenue results and look forward to continued quarter over quarter growth into the foreseeable future,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. One of the most important areas of focus for us going forward will be to cut cost and reach profitability as soon as possible, he added.

 

About Sunshine Biopharma

 

Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 51 generic prescription drugs on the market in Canada and 41 additional employees. The Company is planning to expand its product offering to a total of 67 generic prescription drugs by the end of 2024. In parallel, Sunshine Biopharma is continuing its proprietary drug development program which is comprised of (i) K1.1 mRNA for liver cancer, and (ii) PLpro protease inhibitor for COVID-19. For more information, please visit: www.sunshinebiopharma.com.

 

Safe Harbor Forward-Looking Statements

 

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain eve nts could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

 

For Additional Information:

 

Sunshine Biopharma Contact:

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 4 sbfm-20231113.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 sbfm-20231113_def.xml XBRL DEFINITION FILE EX-101.LAB 6 sbfm-20231113_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Common Stock Purchase Warrants [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 sbfm-20231113_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 13, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 13, 2023
Entity File Number 001-41282
Entity Registrant Name SUNSHINE BIOPHARMA, INC.
Entity Central Index Key 0001402328
Entity Tax Identification Number 20-5566275
Entity Incorporation, State or Country Code CO
Entity Address, Address Line One 6500 Trans-Canada Highway
Entity Address, Address Line Two 4th Floor
Entity Address, City or Town Pointe-Claire
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H9R0A5
City Area Code (514)
Local Phone Number 426-6161
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol SBFM
Security Exchange Name NASDAQ
Common Stock Purchase Warrants [Member]  
Title of 12(b) Security Common Stock Purchase Warrants
Trading Symbol SBFMW
Security Exchange Name NASDAQ
XML 9 sunshine_8k_htm.xml IDEA: XBRL DOCUMENT 0001402328 2023-11-13 2023-11-13 0001402328 us-gaap:CommonStockMember 2023-11-13 2023-11-13 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2023-11-13 2023-11-13 iso4217:USD shares iso4217:USD shares false 0001402328 8-K 2023-11-13 SUNSHINE BIOPHARMA, INC. CO 001-41282 20-5566275 6500 Trans-Canada Highway 4th Floor Pointe-Claire QC CA H9R0A5 (514) 426-6161 Common Stock, par value $0.001 SBFM NASDAQ Common Stock Purchase Warrants SBFMW NASDAQ false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " <80 M !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " '2&U7)!Z;HJT #X 0 M&@ @ $F$@ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " '2&U799!YDAD! #/ P $P @ $+$P I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" !5% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sunshinebiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sbfm-20231113.xsd sbfm-20231113_def.xml sbfm-20231113_lab.xml sbfm-20231113_pre.xml sunshine_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sunshine_8k.htm": { "nsprefix": "SBFM", "nsuri": "http://sunshinebiopharma.com/20231113", "dts": { "schema": { "local": [ "sbfm-20231113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "sbfm-20231113_def.xml" ] }, "labelLink": { "local": [ "sbfm-20231113_lab.xml" ] }, "presentationLink": { "local": [ "sbfm-20231113_pre.xml" ] }, "inline": { "local": [ "sunshine_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://sunshinebiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "SBFM_CommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20231113", "localname": "CommonStockPurchaseWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants [Member]" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001683168-23-007924-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-23-007924-xbrl.zip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end